News

Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition. Under the 2013 partnership agreements, Astellas and Mitobridge have collaborated to discover and develop

MOR202 is MorphoSys's proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in relapsed/refractory multiple myeloma has been concluded. Under the terms

A human monoclonal antibody, Repatha has been designed to suppress proprotein convertase subtilisin/kexin type 9 (PCSK9). It is now the first PCSK9 inhibitor to be approved in the

The round was led by OrbiMed and included participation from Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio. This financing brings the total

The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent

Sublocade’s approval is for patients who had started treatment with a transmucosal buprenorphine-containing product and have been on a stable dose of the treatment for at least seven

Based on the Phase 2 safety and efficacy results, along with guidance from the FDA and EMA, Revance plans to proceed to a Phase 3 program in cervical

This includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline).  The acquisition was unanimously approved by Melinta’s

Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study, dubbed Strive.  Erenumab functions by targeting and inhibiting the Calcitonin Gene-Related Peptide